SCHEMBL4154884

SCHEMBL4154884

CCCS(=O)(=O)Nc1cc(C(C)(C)C)c(O)c(C(=O)Nc2ccc(C#N)cc2OC(F)(F)F)c1C

nearest known ligand 0.40

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
PGR P06401 1/20 0.40
BRAF P15056 14/20 0.38
GCGR P47871 1/20 0.37
ALDH1A1 P00352 1/20 0.35
HSD17B10 Q99714 1/20 0.35
CNR2 P34972 1/20 0.33
PTGES2 Q9H7Z7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4146555 0.94 PGR (0.45) PGRGCGRALDH1A1CNR2
SCHEMBL4138666 0.89 GCGR (0.39) PGRGCGRALDH1A1CNR2
SCHEMBL4133940 0.87 GCGR (0.36) PGRGCGRCNR2
SCHEMBL4140219 0.85 GCGR (0.38) GCGRALDH1A1CNR2
SCHEMBL4146334 0.85 CNR2 (0.38) PGRGCGRCNR2
SCHEMBL3170148 0.84 PTGFR (0.39) GCGRCNR2
SCHEMBL4148816 0.84 GCGR (0.38) PGRGCGRCNR2
SCHEMBL4149540 0.83 GCGR (0.39) GCGRCNR2
SCHEMBL4150028 0.83 GCGR (0.39) GCGRCNR2
SCHEMBL4146506 0.83 GCGR (0.39) GCGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090062396-A1 Novel Haloalkoxy-Substituted Salicylic Anilides NOVO NORDISK A/S (DK) 2009-03-05 US claimed
EP-1888508-A2 NOVEL HALOALKOXY-SUBSTITUTED SALICYLIC ANILIDES NOVO NORDISK A/S (DK) 2008-02-20 EP claimed
WO-2006125781-A2 HALOALKOXY-SUBSTITUTED SALICYLIC ANILIDES NOVO NORDISK A/S (DK) 2006-11-30 WO claimed
US-10849867-B2 Methods and compositions for treating conditions associated with an abnormal inflammatory response FIRST WAVE BIO, INC. (US) 2020-12-01 US disclosed
US-10799468-B2 Methods and compositions for treating conditions associated with an abnormal inflammatory responses FIRST WAVE BIO, INC. (US) 2020-10-13 US disclosed
US-10772854-B2 Methods and compositions for treating conditions associated with an abnormal inflammatory response FIRST WAVE BIO, INC. (US) 2020-09-15 US disclosed
US-20200276140-A1 METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES FIRST WAVE BIO, INC. 2020-09-03 US disclosed
US-20200268694-A1 METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES FIRST WAVE BIO, INC. 2020-08-27 US disclosed
US-20200147013-A1 METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES FIRST WAVE BIO, INC. 2020-05-14 US disclosed
US-20190298670-A1 METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES MONTERESEARCH S.R.L. (IT) 2019-10-03 US disclosed
US-20090062396-A1 Novel Haloalkoxy-Substituted Salicylic Anilides NOVO NORDISK A/S (DK) 2009-03-05 US disclosed
EP-1888508-A2 NOVEL HALOALKOXY-SUBSTITUTED SALICYLIC ANILIDES NOVO NORDISK A/S (DK) 2008-02-20 EP disclosed
WO-2006125781-A2 HALOALKOXY-SUBSTITUTED SALICYLIC ANILIDES NOVO NORDISK A/S (DK) 2006-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200268694-A1 METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES FH, CS, ECHS1 PGR 4091/4885BRAF 3578/4885GCGR 1824/4885
US-20190298670-A1 METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES FH, CS, ECHS1 PGR 4091/4885BRAF 3578/4885GCGR 1824/4885
US-10849867-B2 Methods and compositions for treating conditions associated with an abnormal inflammatory response FH, CS, ECHS1 PGR 4000/4885BRAF 3532/4885GCGR 1721/4885
US-20090062396-A1 Novel Haloalkoxy-Substituted Salicylic Anilides FABP4, HDHD5, HSPD1 PGR 4874/4885BRAF 3793/4885GCGR 1042/4885
US-10799468-B2 Methods and compositions for treating conditions associated with an abnormal inflammatory responses FH, CS, ECHS1 PGR 4091/4885BRAF 3578/4885GCGR 1824/4885
US-20200147013-A1 METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES FH, CS, ECHS1 PGR 4091/4885BRAF 3578/4885GCGR 1824/4885
US-20200276140-A1 METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES FH, CS, ECHS1 PGR 4091/4885BRAF 3578/4885GCGR 1824/4885
US-10772854-B2 Methods and compositions for treating conditions associated with an abnormal inflammatory response FH, CS, ECHS1 PGR 4000/4885BRAF 3532/4885GCGR 1721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.